Effects of age, postmortem delay and storage time on receptor-mediated activation of G-proteins in human brain

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
J González-MaesoJ Javier Meana

Abstract

The influence of age, postmortem delay and freezing storage period on receptor-mediated G-protein activity was quantified in cortical membranes from 34 healthy subjects. Concentration-response curves of the [(35)S]GTPgammaS binding stimulation by agonists for alpha(2)-adrenoceptors (UK14304), mu-opioid (DAMGO), 5-HT(1A) (8-OH-DPAT), GABA(B) (baclofen) and muscarinic (carbachol) receptors were analyzed. Immunoreactivities of G(alpha)-protein subunits were also determined. Basal binding and UK14304, 8-OH-DPAT, and baclofen potency to stimulate [(35)S]GTPgammaS binding decreased with aging (1-88 years) without changes of efficacy. DAMGO-mediated stimulation increased both in potency and efficacy with aging. A negative correlation between age and immunoreactivity was observed for G(alphai1/2)-, but not for G(alphai3)-, G(alphao)-,and G(alphas)-proteins. Neither [(35)S]GTPgammaS binding nor G(alpha)-proteins changed with the postmortem delay (8-92 h). Basal [(35)S]GTPgammaS binding decreased with the sample storage period (1-85 months). A careful match between cases and controls should be taken into account when designing signal transduction studies in human disorders, specially for variables such as age and storage period.

Citations

Nov 12, 2003·Life Sciences·C Harrison, J R Traynor
Sep 27, 2002·European Journal of Pharmacology·Javier González-MaesoJ Javier Meana
Oct 5, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert E McCullumsmithJames H Meador-Woodruff
May 28, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Beata KarolewiczGregory A Ordway
Jul 22, 2014·Neuropeptides·G Barreda-GómezR Rodríguez-Puertas
Sep 8, 2010·Neurochemistry International·Guadalupe RiveroJ Javier Meana
Mar 10, 2009·Trends in Neurosciences·Javier González-Maeso, Stuart C Sealfon
Mar 18, 2016·Naunyn-Schmiedeberg's Archives of Pharmacology·Monika FeliszekEberhard Schlicker
Jan 4, 2005·Neurochemistry International·Maria C OlianasPierluigi Onali
Sep 27, 2005·European Journal of Pharmacology·Yuji Odagaki, Ryoichi Toyoshima
Apr 11, 2015·Journal of Neurochemistry·Estibaliz González de San RománRafael Rodríguez-Puertas
Dec 7, 2018·Basic & Clinical Pharmacology & Toxicology·Yuji OdagakiJesús A García-Sevilla
Aug 8, 2017·Nature Neuroscience·Daisuke IbiJavier González-Maeso
Jun 16, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jerry LeePeter Hevezi
May 13, 2005·Journal of Pharmacological Sciences·Yuji Odagaki, Ryoichi Toyoshima
May 21, 2019·Frontiers in Aging Neuroscience·Patrícia G de OliveiraSandra I Vieira
Feb 4, 2021·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Pierre-Eric LutzGustavo Turecki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.